These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 22072801

  • 21. Phase I trial of SU14813 in patients with advanced solid malignancies.
    Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R, Abbattista A, Shalinsky DR, Bokemeyer C, Boven E.
    Ann Oncol; 2011 Jan; 22(1):195-201. PubMed ID: 20605934
    [Abstract] [Full Text] [Related]

  • 22. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
    Bavcar S, Argyle DJ.
    Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
    [Abstract] [Full Text] [Related]

  • 23. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF, Blum HE, Geissler M.
    Dtsch Med Wochenschr; 2005 May 27; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract] [Full Text] [Related]

  • 24. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM.
    Clin Cancer Res; 2003 Jul 27; 9(7):2755-68. PubMed ID: 12855656
    [Abstract] [Full Text] [Related]

  • 25. Enzastaurin.
    Chen YB, LaCasce AS.
    Expert Opin Investig Drugs; 2008 Jun 27; 17(6):939-44. PubMed ID: 18491994
    [Abstract] [Full Text] [Related]

  • 26. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
    Ogawara K, Abe S, Un K, Yoshizawa Y, Kimura T, Higaki K.
    J Pharm Sci; 2014 Aug 27; 103(8):2464-9. PubMed ID: 24985750
    [Abstract] [Full Text] [Related]

  • 27. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
    Stahtea XN, Kousidou OCh, Roussidis AE, Tzanakakis GN, Karamanos NK.
    Connect Tissue Res; 2008 Aug 27; 49(3):211-4. PubMed ID: 18661345
    [Abstract] [Full Text] [Related]

  • 28. [Anti-tumor effect of E7080, a novel angiogenesis inhibitor].
    Koyama N, Magario N, Yamamoto Y, Matsui J, Tsuruoka A.
    Nihon Yakurigaku Zasshi; 2008 Aug 27; 132(2):100-4. PubMed ID: 18689959
    [No Abstract] [Full Text] [Related]

  • 29. Pharmacia's SU5416 not effective.
    Expert Rev Anticancer Ther; 2002 Feb 27; 2(1):5. PubMed ID: 12113066
    [No Abstract] [Full Text] [Related]

  • 30. Anaplastic lymphoma kinase inhibitors.
    Crescenzo R, Inghirami G.
    Curr Opin Pharmacol; 2015 Aug 27; 23():39-44. PubMed ID: 26051994
    [Abstract] [Full Text] [Related]

  • 31. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
    Antoniu SA, Kolb MR.
    IDrugs; 2010 May 27; 13(5):332-45. PubMed ID: 20432191
    [Abstract] [Full Text] [Related]

  • 32. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA.
    Cancer Treat Rev; 2011 Dec 27; 37(8):611-7. PubMed ID: 21641723
    [Abstract] [Full Text] [Related]

  • 33. Tumour-agnostic drugs and future cancer treatment.
    Børset M.
    Tidsskr Nor Laegeforen; 2019 Mar 12; 139(5):. PubMed ID: 30872821
    [No Abstract] [Full Text] [Related]

  • 34. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C, Bani MR, Giavazzi R.
    Tumori; 2001 Mar 12; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract] [Full Text] [Related]

  • 35. Early development of sunitinib in hepatocellular carcinoma.
    Zhu AX, Raymond E.
    Expert Rev Anticancer Ther; 2009 Jan 12; 9(1):143-50. PubMed ID: 19105714
    [Abstract] [Full Text] [Related]

  • 36. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S, Crescenzi E, Fedele M, Cerchia L.
    Biochim Biophys Acta Rev Cancer; 2018 Apr 12; 1869(2):263-277. PubMed ID: 29574128
    [Abstract] [Full Text] [Related]

  • 37. Sunitinib for the treatment of thyroid cancer.
    Gómez-Sáez JM.
    Expert Opin Investig Drugs; 2016 Nov 12; 25(11):1345-1352. PubMed ID: 27677828
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
    Rijavec E, Genova C, Barletta G, Biello F, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Boccardo F, Grossi F.
    Expert Opin Pharmacother; 2014 Aug 12; 15(12):1771-80. PubMed ID: 25032887
    [Abstract] [Full Text] [Related]

  • 39. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P.
    Expert Opin Ther Targets; 2003 Apr 12; 7(2):215-34. PubMed ID: 12667099
    [Abstract] [Full Text] [Related]

  • 40. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM.
    Tidsskr Nor Laegeforen; 2005 Nov 17; 125(22):3115-9. PubMed ID: 16299568
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.